| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.1M | — | +798.5% |
| Cost of Revenue | $2.0M | — | +694.8% |
| Gross Profit | $1.1M | — | +1077.4% |
| R&D Expense | $1.0M | — | -14.9% |
| SG&A Expense | $1.4M | — | +55.1% |
| Operating Income | -$1.8M | — | +48.9% |
| Net Income | -$1.7M | — | +50.8% |
| EPS (Basic) | -$0.43 | — | -258.3% |
| EPS (Diluted) | -$0.43 | — | -258.3% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $36.6M | +251.9% | +263.0% |
| Accounts Receivable | $3.2M | +7.1% | +926.0% |
| Inventory | $1.3M | -16.7% | +95.2% |
| Current Assets | $44.2M | +188.6% | +272.0% |
| Total Assets | $45.6M | +172.3% | +240.8% |
| Current Liabilities | $2.4M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.6M | — | -19.4% |
| Capital Expenditures | $38K | — | +81.0% |
| Investing Cash Flow | -$38K | — | -81.0% |
| Financing Cash Flow | $31.8M | — | +137.0% |
| Free Cash Flow | -$5.6M | — | -19.6% |
| -18.3% |
| Total Liabilities | $2.8M | -33.3% | -27.1% |
| Stockholders' Equity | $42.8M | +242.1% | +350.3% |